Hints and tips:
...The NPS said it has yet to decide whether to increase its Kosdaq weighting. The government is also planning to introduce a new market index that incorporates Kospi and Kosdaq companies....
...The group’s status as one of the fastest-growing companies in the pharmaceuticals sector was reinforced on Friday by first-quarter results which showed a 15 per cent increase in sales to $1.71bn and a 15...
...In addition to Baxalta, Shire bought two other US biotech companies, NPS and Dyax — each for more than $5bn — in the past year....
...From there, he moved to a series of smaller companies: Bristol-Myers, Vertex, NPS Pharma and Onyx. “Pretty soon, I’ll be washing glassware.”...
...Two deals with NPS Pharma and Dyax followed, but the pursuit of Baxalta was by far the most ambitious....
...He was attracted by the high prices and high unmet medical need associated with that area of the pharmaceuticals market....
...Since then Shire, whose market value is £34bn, has spent $5bn buying NPS Pharmaceuticals, allowing it to apply its low corporate tax rate (it paid an effective rate of 17 per cent in 2014) to a new stream...
...Mr Ornskov added that he remained on the lookout for acquisition targets even after this latest deal, which follows a $5.2bn takeover of NPS Pharmaceuticals in January and a $300m acquisition of an eyecare...
...In January it bought a US rare disease specialist called NPS for $5.2bn....
...To that end, it recently bought NPS, a US-based rare disease specialist, for $5.2bn and is in the throes of a $30bn hostile takeover attempt of Baxalta, another US group, which focuses on rare blood disorders...
...Shire’s $5.2bn acquisition of NPS Pharmaceuticals on Sunday was the latest example of a larger drugmaker making a big gamble on a smaller biotech company whose prospects are heavily dependent on regulatory...
...drugs than NPS would have been on its own, or both....
...Shire, Britain’s third-largest drugmaker by market value, has made its biggest ever acquisition with a $5.2bn deal for US biotechnology company NPS Pharmaceuticals, as the FTSE 100 group looks to build its...
...It came a week after the FDA gave its blessing to a treatment for the rare hormonal disorder hypoparathyroidism developed by NPS Pharmaceuticals, which last month agreed to be bought by Shire for $5.2bn....
...Once the prey, now the predator, Shire makes its biggest acquisition by buying the US biotechnology company NPS for $5.2bn....
...Fears that Shire has overpaid for NPS Pharmaceuticals looked misplaced, UBS said, as acquired treatments for low blood calcium and short bowel syndrome “should both become blockbuster products over time”...
...Flemming Ørnskov, Shire chief executive, told the Financial Times he was focused on integration of NPS pharma, acquired for $5.2bn in January....
...Shire has already committed the break fee to help finance its $5.2bn acquisition of US-based NPS Pharmaceuticals, agreed last month, as it resumes its expansion as a standalone company focused on speciality...
...Roche, Johnson & Johnson and Biogen Idec were among drugmakers to announce tie-ups on Monday, a day after Shire agreed to buy NPS Pharmaceuticals for $5.2bn....
...Shire will pay £3.2bn for US biotech business NPS Pharmaceuticals. That equates to $46 a share — a 51 per cent premium to the NPS share price on 16 December 2014....
...The company last month agreed to buy NPS, a US rare disease specialist, for $5.2bn — its biggest acquisition so far....
...The collapse of AbbVie’s takeover of Shire was one of the most dramatic episodes in a tumultuous year of dealmaking across the pharmaceuticals sector....
...The transaction comes after Pfizer announced a $17bn deal to buy Hospira earlier this month and after Shire acquired NPS for $5.2bn in January, suggesting that consolidation in the pharmaceutical industry...
...There is a new pharmaceuticals giant in town....
...Valeant announced a $14.5bn deal to acquire Salix over the weekend; Pfizer announced a $17bn deal to buy Hospira earlier this month; and UK-listed Shire acquired NPS in a $5.2bn deal in January....
International Edition